Literature DB >> 31782186

Japanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019.

Yasuhiro Nakamura1, Jun Asai2, Hiroshi Igaki3, Takashi Inozume4, Kenjiro Namikawa5, Ayato Hayashi6, Satoshi Fukushima7, Taku Fujimura8, Takamichi Ito9, Keisuke Imafuku10, Ryota Tanaka11, Yukiko Teramoto1, Akane Minagawa12, Takuya Miyagawa13, Azusa Miyashita7, Makoto Wada2, Hiroshi Koga12, Makoto Sugaya14.   

Abstract

With consideration of the ongoing developments in treatment options for cutaneous melanoma, the Japanese Skin Cancer Society published the first guidelines for cutaneous melanoma in 2007 and later revised them in 2015. Here, we report on an English version of the 2019 Japanese Melanoma Guidelines. In this latest edition, all processes were carried out according to the Grading of Recommendations, Assessment, Development and Evaluation system. A comprehensive published work search, systematic review and determination of recommendations in each clinical question were performed by a multidisciplinary expert panel consisting of dermatologists, a plastic and reconstructive surgeon, and a radiation oncologist. The advent of novel agents, such as immune checkpoint inhibitors and molecular-targeted agents, has drastically changed the nature of treatment for adjuvant and advanced-stage diseases among melanoma patients worldwide. Additionally, recent reports of clinical trials regarding surgical procedures and a better understanding of molecular biology and tumor immunology in clinical types of melanoma have had an impact on clinical practise. Based on these viewpoints, eight relevant clinical questions were raised in this report that aim to help clinicians select the appropriate therapeutic approach.
© 2019 Japanese Dermatological Association.

Entities:  

Keywords:  cutaneous melanoma; grade system; guidelines; immune checkpoint inhibitor; molecular-targeted agent

Mesh:

Year:  2019        PMID: 31782186     DOI: 10.1111/1346-8138.15151

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  9 in total

1.  Evaluation of the reporting quality of clinical practice guidelines on melanoma using the RIGHT checklist.

Authors:  Yongjie Yang; Yanfang Ma; Jingli Lu; Qiwen Zhang; Kelei Guan; Kefeng Liu; Jian Kang; Shuzhang Du; Shu Tang; Xuehui Liu; Ailing Zhang; Dirk Schadendorf; Sanjiv S Agarwala; Xiaojian Zhang
Journal:  Ann Transl Med       Date:  2021-07

Review 2.  Current Treatment Approaches and Global Consensus Guidelines for Brain Metastases in Melanoma.

Authors:  Xiang-Lin Tan; Amy Le; Fred C Lam; Emilie Scherrer; Robert G Kerr; Anthony C Lau; Jiali Han; Ruixuan Jiang; Scott J Diede; Irene M Shui
Journal:  Front Oncol       Date:  2022-05-05       Impact factor: 5.738

3.  Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy.

Authors:  Yumi Kambayashi; Kentaro Ohuchi; Hiromu Chiba; Erika Tamabuchi; Tasuku Nagasawa; Yoshihide Asano; Taku Fujimura
Journal:  Case Rep Oncol       Date:  2022-05-02

Review 4.  BRAF Heterogeneity in Melanoma.

Authors:  Takamichi Ito; Yuka Tanaka; Maho Murata; Yumiko Kaku-Ito; Kazuhisa Furue; Masutaka Furue
Journal:  Curr Treat Options Oncol       Date:  2021-02-08

Review 5.  Appraisal of International Guidelines for Cutaneous Melanoma Management using the AGREE II assessment tool.

Authors:  C Jacklin; M Tan; S Sravanam; C J Harrison
Journal:  JPRAS Open       Date:  2021-12-08

6.  Rapidly Changing Serous Detachment During BRAF and MEK Inhibitor Therapy.

Authors:  Chisato Agata; Kohdai Kitamoto; Kohei Ueda; Keiko Azuma; Tatsuya Inoue; Ryo Obata
Journal:  Cureus       Date:  2021-12-17

7.  A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma.

Authors:  Naoya Yamazaki; Taiki Isei; Yoshio Kiyohara; Hiroshi Koga; Takashi Kojima; Tatsuya Takenouchi; Kenji Yokota; Kenjiro Namikawa; Min Yi; Alissa Keegan; Satoshi Fukushima
Journal:  Cancer Sci       Date:  2022-06-30       Impact factor: 6.518

8.  Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy-naive advanced melanoma.

Authors:  Kenjiro Namikawa; Yoshio Kiyohara; Tatsuya Takenouchi; Hisashi Uhara; Hiroshi Uchi; Shusuke Yoshikawa; Sumiko Takatsuka; Hiroshi Koga; Naoko Wada; Hironobu Minami; Masahiro Hatsumichi; Yoshinobu Namba; Naoya Yamazaki
Journal:  J Dermatol       Date:  2020-08-18       Impact factor: 4.005

9.  Prospective observational study of the efficacy of nivolumab in Japanese patients with advanced melanoma (CREATIVE study).

Authors:  Naoya Yamazaki; Tatsuya Takenouchi; Yasuhiro Nakamura; Akira Takahashi; Kenjiro Namikawa; Shigehisa Kitano; Tomonobu Fujita; Kazumi Kubota; Takeharu Yamanaka; Yutaka Kawakami
Journal:  Jpn J Clin Oncol       Date:  2021-08-01       Impact factor: 3.019

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.